PROVIDER BULLETIN PROVIDER INFORMATION



November 1, 2021

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue **Cross and Blue Shield of Alabama**

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

Complete our medical policy feedback form online at https://mn-policies.exploremyplan.com/portal/web/mn-<u>policies/feedback</u> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center Attn: Health Management - Medical Policy P.O. Box 10527 Birmingham, AL 35202 Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at Policies & Guidelines (exploremyplan.com)

Policy #	Policy Title
MP-455	Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
MP-713	Liposuction
MP-743	Adjunctive Techniques for Screening and Surveillance of Barrett Esophagus and Esophageal Dysplasia
MP-744	Cryoablation for Chronic Rhinitis

Draft Provider-Administered Drug Policies

Draft Provider-Administerd Drug Policies can be found at Policies & Guidelines (exploremyplan.com)

Policy #	Policy Title
PH-0615	Nexviazyme [™] (avalglucosidase alfa-ngpt)
PH-0614	Saphnelo™ (anifrolumab-fnia)
PH-90027	Cerezyme [®] (imiglucerase)
PH-90105	Elelyso TM (taliglucerase alfa)
PH-90079	Lumizyme [®] (alglucosidase alfa)
PH-90141	VPRIV [®] (velaglucerase alfa)

Bulletin P74-21

Distribution: bluecrossmn.com/providers/forms-and-publications Blue Cross® and Blue Shield® of Minnesota and Blue Plu of Minnesota and Blue Plus[®] are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

PH-90120	Synagis [®] (palivizumab)
PH-9406	Rituxan, Truxima, Ruxience, Riabni (rituximab)